Anti-VEGF-related thrombotic microangiopathy in a child presenting with nephrotic syndrome

YILMAZ S., ÖZÇAKAR Z. B., Taktak A., KİREMİTCİ S., ENSARİ A., DİNÇASLAN H., ...More

PEDIATRIC NEPHROLOGY, vol.31, no.6, pp.1029-1032, 2016 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 31 Issue: 6
  • Publication Date: 2016
  • Doi Number: 10.1007/s00467-016-3355-z
  • Journal Name: PEDIATRIC NEPHROLOGY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.1029-1032
  • Keywords: Thrombotic microangiopathy, Bevacizumab, Anti-VEGF, Nephrotic syndrome, Child, TARGETED THERAPY, BEVACIZUMAB, ANGIOGENESIS, INHIBITION, SORAFENIB, TOXICITY
  • Ankara University Affiliated: Yes

Abstract

Targeting the vascular endothelial growth factor (VEGF) signaling pathway has become an important approach to current cancer therapy. Anti-VEGF therapy-related renal adverse effects may present as hypertension, non-nephrotic proteinuria, and rarely as nephrotic syndrome (NS) and acute kidney injury.